Genetic testing at a distance is commonplace where members of a family with a segregating germline mutation are geographically separated. For the most part, this challenge is addressed through the intervention of health professionals in taking and/or processing blood samples for subsequent couriering of DNA to a referral laboratory. In some circumstances, however, the collecting of pivotal clinical material may involve direct patient involvement. We describe such a situation where noninvasive saliva samples were provided by members of a family manifesting Von Hippel-Lindau (VHL) disease. The analysis identified a novel mutation in the VHL gene that was used to exclude other family members as being at risk of VHL disease. 1. Introduction Von Hippel-Lindau (VHL) disease is an autosomal dominant familial cancer syndrome with a prevalence of approximately 1/39,000 births [1]. The most common tumours in VHL disease are renal cell carcinomas (RCCs), retinal and central nervous system haemangioblastomas, phaeochromocytomas, pancreatic islet tumours, and endolymphatic sac tumours (ELSTs) [2]. In patients with a family history of VHL, a diagnosis can be made with the finding of a single retinal or cerebellar haemangioblastoma, a phaeochromocytoma, or an RCC [3]. In the absence of a family history, a diagnosis can be made with two or more retinal or cerebellar haemangioblastomas or one haemangioblastoma and one visceral tumour [3]. Families can be characterised by the absence (type 1) or presence (type 2) of phaeochromocytomas [4]. VHL disease is due to germline mutation in the VHL tumour suppressor gene, which is located on the short arm of chromosome 3 [5]. The gene comprises three exons and encodes for two proteins: 30?kD (pVHL30, NP_000542.1 expressed from NM_000551.3; transcript variant 1) and 18?kD (pVHL18, NP_937799.1 expressed from NM_198156.2; transcript variant 2) [6]. The shorter pVHL18 protein is generated from alternative translation that starts from an internal methionine at codon 54 [6]. In nude mouse xenograft assays, both the pVHL30 (wildtype) and pVHL18 proteins function as tumour suppressors when introduced into clear-cell RCC cell lines lacking functioning VHL genes [6]. Over 1000 somatic and germline VHL gene mutations have been documented [7], although the web-accessible database at http://databases.lovd.nl/genomed/home.php?select_db=VHL, updated January 14, 2013, shows 430 unique variants with 18 of these identified using tumour samples. Nordstrom-O’Brien et al. report a mutation spectrum of 43.2% in exon 1, 17% in exon 2, and 39.8% in exon
References
[1]
H. P. H. Neumann and O. D. Wiestler, “Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus,” Lancet, vol. 337, no. 8749, pp. 1052–1054, 1991.
[2]
J. A. Butman, W. M. Linehan, and R. R. Lonser, “Neurologic manifestations of von Hippel-Lindau disease,” Journal of the American Medical Association, vol. 300, no. 11, pp. 1334–1342, 2008.
[3]
K. L. Melmon and S. W. Rosen, “Lindau's disease: review of the literature and study of a large kindred,” The American Journal of Medicine, vol. 36, no. 4, pp. 595–617, 1964.
[4]
C. A. Friedrich, “Genotype-phenotype correlation in von Hippel-Lindau syndrome,” Human Molecular Genetics, vol. 10, no. 7, pp. 763–767, 2001.
[5]
F. Latif, K. Tory, J. Gnarra et al., “Identification of the von Hippel-Lindau disease tumor suppressor gene,” Science, vol. 260, no. 5112, pp. 1317–1320, 1993.
[6]
C. Blankenship, J. G. Naglich, J. M. Whaley, B. Seizinger, and N. Kley, “Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity,” Oncogene, vol. 18, no. 8, pp. 1529–1535, 1999.
[7]
M. Nordstrom-O'Brien, R. B. van der Luijt, E. van Rooijen et al., “Genetic analysis of von Hippel-Lindau disease,” Human Mutation, vol. 31, no. 5, pp. 521–537, 2010.
[8]
F. Chen, T. Kishida, M. Yao et al., “Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype,” Human Mutation, vol. 5, no. 1, pp. 66–75, 1995.
[9]
C. Gallou, D. Joly, A. Méjean et al., “Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC,” Human Mutation, vol. 13, no. 6, pp. 464–475, 1999.
[10]
N. L. Rogers, S. A. Cole, H. C. Lan, and A. Crossa, “New saliva DNA collection method compared to buccal cell collection techniques for epidemiological studies,” American Journal of Human Biology, vol. 19, no. 3, pp. 319–326, 2007.
[11]
K. M. Lonergan, O. Iliopoulos, M. Ohh et al., “Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2,” Molecular and Cellular Biology, vol. 18, no. 2, pp. 732–741, 1998.
[12]
M. Ohh, C. W. Park, M. Ivan et al., “Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel—indau protein,” Nature Cell Biology, vol. 2, no. 7, pp. 423–427, 2000.
[13]
P. Jaakkola, D. R. Mole, Y. M. Tian et al., “Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation,” Science, vol. 292, no. 5516, pp. 468–472, 2001.
[14]
J. H. Min, H. Yang, M. Ivan, F. Gertler, W. G. Kaelin Jr., and N. P. Pavietich, “Structure of an HIF-1α-pVHL complex: hydroxyproline recognition in signaling,” Science, vol. 296, no. 5574, pp. 1886–1889, 2002.
[15]
S. Sikora and A. Godzik, “Combination of multiple alignment analysis and surface mapping paves a way for a detailed pathway reconstruction—the case of VHL (von Hippel-Lindau) protein and angiogenesis regulatory pathway,” Protein Science, vol. 13, no. 3, pp. 786–796, 2004.
[16]
A. McNeill, E. Rattenberry, R. Barber, P. Killick, F. MacDonald, and E. R. Maher, “Genotype-phenotype correlations in VHL exon deletions,” American Journal of Medical Genetics A, vol. 149, no. 10, pp. 2147–2151, 2009.